Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 18 studies | 40% ± 17% | |
epithelial cell | 6 studies | 31% ± 6% | |
erythrocyte | 6 studies | 51% ± 18% | |
endothelial cell | 5 studies | 20% ± 3% | |
erythroblast | 5 studies | 43% ± 22% | |
macrophage | 5 studies | 21% ± 6% | |
non-classical monocyte | 4 studies | 34% ± 14% | |
myeloid cell | 4 studies | 20% ± 4% | |
basal cell | 4 studies | 35% ± 9% | |
glutamatergic neuron | 4 studies | 31% ± 13% | |
deuterosomal cell | 3 studies | 23% ± 4% | |
retinal ganglion cell | 3 studies | 42% ± 21% | |
cardiac muscle cell | 3 studies | 21% ± 2% | |
GABAergic neuron | 3 studies | 32% ± 7% | |
astrocyte | 3 studies | 21% ± 4% | |
transit amplifying cell | 3 studies | 28% ± 11% | |
oligodendrocyte precursor cell | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3389.40 | 1445 / 1445 | 100% | 46.64 | 183 / 183 |
ovary | 100% | 2150.73 | 180 / 180 | 100% | 48.83 | 430 / 430 |
skin | 100% | 4195.94 | 1809 / 1809 | 100% | 40.68 | 472 / 472 |
uterus | 100% | 2451.06 | 170 / 170 | 100% | 79.25 | 459 / 459 |
brain | 100% | 3260.85 | 2639 / 2642 | 100% | 74.77 | 705 / 705 |
intestine | 100% | 3430.28 | 966 / 966 | 100% | 49.92 | 526 / 527 |
liver | 100% | 1386.68 | 226 / 226 | 100% | 27.66 | 405 / 406 |
thymus | 100% | 2142.32 | 652 / 653 | 100% | 50.61 | 604 / 605 |
kidney | 100% | 2244.44 | 89 / 89 | 100% | 41.71 | 898 / 901 |
stomach | 100% | 1932.97 | 359 / 359 | 100% | 42.80 | 285 / 286 |
bladder | 100% | 2833.48 | 21 / 21 | 99% | 52.57 | 501 / 504 |
prostate | 100% | 2890.62 | 245 / 245 | 99% | 44.41 | 499 / 502 |
lung | 99% | 2246.24 | 575 / 578 | 100% | 49.99 | 1154 / 1155 |
breast | 100% | 2231.30 | 459 / 459 | 99% | 46.76 | 1111 / 1118 |
adrenal gland | 100% | 2104.19 | 258 / 258 | 98% | 34.41 | 226 / 230 |
pancreas | 96% | 1054.34 | 314 / 328 | 99% | 42.70 | 177 / 178 |
eye | 0% | 0 | 0 / 0 | 100% | 36.39 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 56.83 | 29 / 29 |
muscle | 100% | 15877.34 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2345.98 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 104.19 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 36.06 | 1 / 1 |
adipose | 100% | 2250.99 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2099.38 | 1331 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1974.08 | 920 / 929 | 0% | 0 | 0 / 0 |
heart | 98% | 3856.23 | 848 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0051604 | Biological process | protein maturation |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005886 | Cellular component | plasma membrane |
GO_0031593 | Molecular function | polyubiquitin modification-dependent protein binding |
GO_0070628 | Molecular function | proteasome binding |
GO_0005515 | Molecular function | protein binding |
Gene name | UBAC1 |
Protein name | Ubiquitin-associated domain-containing protein 1 (UBA domain-containing protein 1) (Glialblastoma cell differentiation-related protein 1) (Kip1 ubiquitination-promoting complex protein 2) |
Synonyms | KPC2 UBADC1 GBDR1 |
Description | FUNCTION: Non-catalytic component of the KPC complex, a E3 ubiquitin-protein ligase complex that mediates polyubiquitination of target proteins, such as CDKN1B and NFKB1 . The KPC complex catalyzes polyubiquitination and proteasome-mediated degradation of CDKN1B during G1 phase of the cell cycle . The KPC complex also acts as a key regulator of the NF-kappa-B signaling by promoting maturation of the NFKB1 component of NF-kappa-B by catalyzing ubiquitination of the NFKB1 p105 precursor . Within the KPC complex, UBAC1 acts as an adapter that promotes the transfer of target proteins that have been polyubiquitinated by RNF123/KPC1 to the 26S proteasome . . |
Accessions | ENST00000371756.4 Q9BSL1 |